Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CF PharmTechHKSE:02652 +0.81%15 Quick Ratio is 4.40 as of Dec. 2025, which is 47% above its 10-year median of 3.00. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review. Among 996 Drug Manufacturers companies, CF PharmTech ranks better than 87.05% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. CF PharmTech's quick ratio for the quarter that ended in Dec. 2025 was 4.40.
CF PharmTech has a quick ratio of 4.40. It generally indicates good short-term financial strength.
The historical rank and industry rank for CF PharmTech's Quick Ratio or its related term are showing as below:
HKSE:02652'
s Quick Ratio Range Over the Past 10 Years
Min: 1.69 Med: 3 Max: 4.4
Current: 4.4
During the past 4 years, CF PharmTech's highest Quick Ratio was 4.40. The lowest was 1.69. And the median was 3.00.
HKSE:02652's Quick Ratio is ranked better than 87.05% of 996
companies
in the Drug Manufacturers industry
Industry Median: 1.42
vs HKSE:02652: 4.40
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
CF PharmTech Quick Ratio Related Terms
CF PharmTech Quick Ratio Historical Data
* Premium members only.
The historical data trend for CF PharmTech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech Quick Ratio Chart
CF PharmTech Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Quick Ratio
3.32
2.68
1.69
4.40
CF PharmTech Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Quick Ratio
3.32
2.68
1.69
4.40
HKSE:02652 vs ZTS: Quick Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CF PharmTech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CF PharmTech Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CF PharmTech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where CF PharmTech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
CF PharmTech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CF PharmTech (HKSE:02652) has a Quick Ratio of 4.40 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CF PharmTech and its competitors. This is 47% above median its historical median of 3.00. Over the past decade, CF PharmTech's Quick Ratio has ranged from 1.69 to 4.40. According to the industry distribution chart, CF PharmTech ranks #129 out of 996 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is CF PharmTech's Quick Ratio too high?
CF PharmTech's current Quick Ratio of 4.40 is 47% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.69 to a high of 4.40. The Drug Manufacturers industry median Quick Ratio is 1.42. CF PharmTech's value of 4.40 is 209.9% above this industry median. Based on the distribution chart, CF PharmTech ranks #129 out of 996 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Quick Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CF PharmTech ranks #129 out of 996 companies for Quick Ratio. This places CF PharmTech in the top 13% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.42. CF PharmTech's value of 4.40 is 209.9% above this benchmark. Historically, CF PharmTech's own Quick Ratio has ranged from 1.69 to 4.40 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 1.42, CF PharmTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.42, based on 996 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CF PharmTech's current Quick Ratio of 4.40 is 209.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on CF PharmTech and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CF PharmTech's current Quick Ratio is 4.40, which is 47% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Quick Ratio of 4.40. The current Quick Ratio is 4.40, which is 47% above median its 10-year median of 3.00 and 209.9% above the Drug Manufacturers industry median of 1.42. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Quick Ratio is 4.40 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score
Get the complete analysis for HKSE:02652
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02652 has been successfully added to your 
